TSE:ASP Acerus Pharmaceuticals - ASP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. C$0.36 0.00 (0.00%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's RangeC$0.36▼C$0.3650-Day RangeC$0.28▼C$1.2952-Week RangeC$0.28▼C$10.00VolumeN/AAverage Volume4,719 shsMarket CapitalizationC$2.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsInsider TradesHeadlinesSocial Media About Acerus Pharmaceuticals (TSE:ASP) StockAcerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.Read More Receive ASP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ASP Stock News HeadlinesJanuary 26, 2023 | finance.yahoo.comIIROC Trading Halt - ASPJanuary 26, 2023 | finance.yahoo.comAcerus Files For CCAA ProtectionFebruary 5, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…December 22, 2022 | finance.yahoo.comAcerus Announces New Loan Agreement With First Generation CapitalNovember 18, 2022 | finance.yahoo.comAcerus Pharmaceuticals Third Quarter 2022 Earnings: US$0.54 loss per share (vs US$0.64 loss in 3Q 2021)August 3, 2022 | finance.yahoo.comAcerus to Report Q2-2022 Financial Results and Host Investor CallJune 7, 2022 | finance.yahoo.comAcerus Announces Amendment and Restatement of the Promissory Note Related to the Up-Front Fee Payable to Former Serenity SecurityholdersMay 10, 2022 | finance.yahoo.comAcerus Reports First Quarter 2022 Financial ResultsFebruary 5, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…April 27, 2022 | finanznachrichten.deAcerus Pharmaceuticals Corporation: Acerus Announces Completion of Share ConsolidationMarch 10, 2022 | ca.finance.yahoo.comStocks in play: Acerus Pharmaceuticals Corporation.March 10, 2022 | finance.yahoo.comAcerus To Report Q4 And Full Year 2021 Financial Results And Host Investor CallFebruary 18, 2022 | finance.yahoo.comAcerus Announces Amendment to Loan FacilitiesJanuary 10, 2022 | finance.yahoo.comAcerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO® in Puerto RicoDecember 13, 2021 | finance.yahoo.comAcerus Announces Amendments to Loan FacilitiesNovember 2, 2021 | finance.yahoo.comAcerus to Report Q3-2021 Financial Results and Host Investor CallOctober 26, 2021 | finance.yahoo.comResearch Reports Initiated on Healthcare Stocks Nuvo Pharmaceuticals, Acerus Pharmaceuticals, and AvivagenSeptember 9, 2021 | finance.yahoo.comEven with Acerus Pharmaceuticals Corporation (TSE:ASP) stock down 11% this week, insiders who bought recently netted around US$102kAugust 21, 2021 | barrons.comAcerus Pharmaceuticals Corp.August 12, 2021 | finance.yahoo.comAcerus Reports Acceptance of Part 36 Settlement Offer in Recipharm LitigationAugust 3, 2021 | finance.yahoo.comAcerus to Report Q2-2021 Financial Results and Host Investor CallJuly 12, 2021 | finance.yahoo.comAcerus Provides Update on Litigation with RecipharmJune 29, 2021 | finance.yahoo.comAcerus Announces New PBM Contract, Significantly Expanding NATESTO® Insurance Coverage in the United StatesJune 14, 2021 | finance.yahoo.comAcerus Announces Voting Results for the 2021 Annual MeetingJune 10, 2021 | finance.yahoo.comAcerus Pharmaceuticals'(TSE:ASP) Share Price Is Down 85% Over The Past Three Years.June 2, 2021 | bloomberg.comAcerus Pharmaceuticals CorpMay 13, 2021 | markets.businessinsider.comAcerus Reports First Quarter 2021 Financial ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ASP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ASP Company Calendar Last Earnings11/14/2022Today2/04/2023Next Earnings (Estimated)3/13/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:ASP CUSIPN/A CIKN/A Webwww.aceruspharma.com Phone416-679-0771FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio261.01 Current Ratio0.67 Quick Ratio0.26 Sales & Book Value Annual SalesC$3.04 million Price / Sales0.91 Cash FlowC$0.11 per share Price / Cash Flow3.29 Book ValueC($1.80) per share Price / Book-0.20Miscellaneous Outstanding Shares7,708,000Free FloatN/AMarket CapC$2.77 million OptionableNot Optionable BetaN/A Key ExecutivesMr. Edward GudaitisPres, CEO & DirectorMr. Gavin DamstraSr. VP of International CommercialDr. Christopher Sorli F.A.C.E.M.D., Ph.D., Chief Medical OfficerMr. Kevin Thomas HickeySr. VP of US CommercialMr. Naveed ManzoorInterim Chief Financial OfficerMr. Chris WittyInvestor RelationsMr. Philippe SavardSr. VP, Gen. Counsel & Corp. Sec.Mr. Hubert Tomasz CzerwinskiPres of Acerus Pharmaceuticals SRLMore ExecutivesKey CompetitorsNeutriSci InternationalCVE:NUEve & Co IncorporatedCVE:EVEAequus PharmaceuticalsCVE:AQSSugarBud Craft GrowersCVE:SUGRLattice BiologicsCVE:LBLView All CompetitorsInsiders & InstitutionsEdward Joseph GudaitisBought 500 shares on 5/11/2022Total: C$2,260.00 ($4.52/share)View All Insider Transactions ASP Stock - Frequently Asked Questions How have ASP shares performed in 2023? Acerus Pharmaceuticals' stock was trading at C$0.81 at the beginning of 2023. Since then, ASP shares have decreased by 55.6% and is now trading at C$0.36. View the best growth stocks for 2023 here. When is Acerus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023. View our ASP earnings forecast. How were Acerus Pharmaceuticals' earnings last quarter? Acerus Pharmaceuticals Co. (TSE:ASP) posted its quarterly earnings data on Monday, November, 14th. The company reported ($0.71) EPS for the quarter. The company had revenue of $1.01 million for the quarter. What other stocks do shareholders of Acerus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acerus Pharmaceuticals investors own include Aurora Cannabis (ACB), Surna (SRNA), Allena Pharmaceuticals (ALNA), Molecular Templates (MTEM), Avid Bioservices (CDMO), OHR Pharmaceutical (OHRP), Trilogy International Partners (TRL), Absolute Software Co. (ABT.TO) (ABT), Ampliphi Biosciences (APHB) and Algonquin Power & Utilities (AQN). What is Acerus Pharmaceuticals' stock symbol? Acerus Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ASP." How do I buy shares of Acerus Pharmaceuticals? Shares of ASP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Acerus Pharmaceuticals' stock price today? One share of ASP stock can currently be purchased for approximately C$0.36. How much money does Acerus Pharmaceuticals make? Acerus Pharmaceuticals (TSE:ASP) has a market capitalization of C$2.77 million and generates C$3.04 million in revenue each year. How can I contact Acerus Pharmaceuticals? The official website for the company is www.aceruspharma.com. The company can be reached via phone at 416-679-0771. This page (TSE:ASP) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.